Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes

Current Atherosclerosis Reports

Volumn 11, Issue 2, 2009, Pages 131-138

  Gonzalez Quesada, Carlos ^a   Frangogiannis, Nikolaos G ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR CCR2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; ORBOFIBAN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE COURSE; DISEASE MARKER; DRUG MECHANISM; ENZYME INHIBITION; HEART INFARCTION; HEART INJURY; HUMAN; NONHUMAN; PATHOGENESIS; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TISSUE REPAIR; WOUND HEALING;

ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; CHEMOKINE CCL2; HUMANS;

EID: 60849117539     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-009-0021-y     Document Type: Article

References (48)

1. Buffon A, Biasucci LM, Liuzzo G, et al.: Widespread coronary inflammation in unstable angina. N Engl J Med 2002, 347: 5-12.
2. Libby P: AtDerosclerosis: disease biology affecting the coronary vasculature. Am J Cardiol 2006, 98: 3Q-9Q.
3. Morrow DA, Braunwald E: Future of biomarkers in acute coronary syndromes: Moving toward a multimarker strategy. Circulation 2003, 108: 250-252.
4. Morrow DA, Rifai N, Antman EM, et al.: C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: A TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1998, 31: 1460-1465.
5. Morrow DA, de Lemos JA, Sabatine MS, et al.: Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor trial. Circulation 2006, 114: 281-288.
6. Gerard C, Rollins BJ: Chemokines and disease. Nat Immunol 2001, 2: 108-115.
7. Ceradini DJ, Kulkarni AR, Callaghan MJ, et al.: Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004, 10: 858-864.
8. Nelken NA, Coughlin SR, Gordon D, Wilcox JN: Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991, 88: 1121-1127.
9. Cushing SD, Berliner JA, Valente AJ, et al.: Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A 1990, 87: 5134-5138.
10. Charo IF, Taubman MB: Chemokines in the pathogenesis of vascular disease. Circ Res 2004, 95: 858-866.
11. Gu L, Okada Y, Clinton SK, et al.: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998, 2: 275-281.
12. Gosling J, Slaymaker S, Gu L, et al.: MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999, 103: 773-778.
13. Boring L, Gosling J, Cleary M, Charo IF: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394: 894-897.
14. Dawson TC, Kuziel WA, Osahar TA, Maeda N: Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 1999, 143: 205-211.
15. Ni W, Egashira K, Kitamoto S, et al.: New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 2001, 103: 2096-2101.
16. Salcedo R, Ponce ML, Young HA, et al.: Human endothelial cells express CCR2 and respond to MCP-1: Direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96: 34-40.
17. Doyle B, Caplice N: Plaque neovascularization and anti-angiogenic therapy for atherosclerosis. J Am Coll Cardiol 2007, 49: 2073-2080.
18. Robinson SC, Scott KA, Balkwill FR: Chemokine stimulation of monocyte matrix metalloproteinase-9 requires endogenous TNF-alpha. Eur J Immunol 2002, 32: 404-412.
19. Schecter AD, Rollins BJ, Zhang YJ, et al.: Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem 1997, 272: 28568-28573.
20. Lutgens E, Faber B, Schapira K, et al.: Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody. Circulation 2005, 111: 3443-3452.
21. Inoue S, Egashira K, Ni W, et al.: Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 2002, 106: 2700-2706.
22. Frangogiannis NG: The mechanistic basis of infarct healing. Antioxid Redox Signal 2006, 8: 1907-1939.
23. Frangogiannis NG: Chemokines in ischemia and reperfusion. Thromb Haemost 2007, 97: 738-747.
24. Dewald O, ReS G, Duerr GD, et al.: Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am J Pathol 2004, 164: 665-677.
25. Birdsall HH, Green DM, Trial J, et al.: Complement C5a, TGF-beta 1, and MCP-1, in sequence, induce migration of monocytes into ischemic canine myocardium within the first one to five hours after reperfusion. Circulation 1997, 95: 684-692.
26. Ono K, Matsumori A, Furukawa Y, et al.: Prevention of myocardial reperfusion injury in rats by an antibody against monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 1999, 79: 195-203.
27. Gharaee-Kermani M, Denholm EM, Phan SH: Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996, 271: 17779-17784.
28. Dewald O, Zymek P, Winkelmann K, et al.: CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 2005, 96: 881-889.
29. Kaikita K, Hayasaki T, Okuma T, et al.: Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction. Am J Pathol 2004, 165: 439-447.
30. Frangogiannis NG, Ren G, Dewald O, et al.: The critical role of endogenous thrombospondin (TSP)-1 in preventing expansion of healing myocardial infarcts. Circulation 2005, 111: 2935-2942.
31. Deo R, Khera A, McGuire DK, et al.: Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 2004, 44: 1812-1818.
32. Hoogeveen RC, Morrison A, Boerwinkle E, et al.: Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis 2005, 183: 301-307.
33. Lau EK, Paavola CD, Johnson Z, et al.: Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: Implications for structure and function in vivo. J Biol Chem 2004, 279: 22294-22305.
34. Aukrust P, Halvorsen B, Yndestad A, et al.: Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol 2008 Jul 31 [Epub ahead of print].
35. Aukrust P, Yndestad A, Smith C, et al.: Chemokines in cardiovascular risk prediction. Thromb Haemost 2007, 97: 748-754.
36. Matsumori A, Furukawa Y, Hashimoto T, et al.: Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J Mol Cell Cardiol 1997, 29: 419-423.
37. Nishiyama K, Ogawa H, Yasue H, et al.: Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes. Jpn Circ J 1998, 62: 710-712.
38. Aukrust P, Berge RK, Ueland T, et al.: Interaction between chemokines and oxidative stress: Possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol 2001, 37: 485-491.
39. de Lemos JA, Morrow DA, Sabatine MS, et al.: Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003, 107: 690-695.
40. Kervinen H, Manttari M, Kaartinen M, et al.: Prognostic usefulness of plasma monocyte/macrophage and T-lymphocyte activation markers in patients with acute coronary syndromes. Am J Cardiol 2004, 94: 993-996.
41. Parissis JT, Adamopoulos S, Venetsanou KF, et al.: Serum profiles of C-C chemokines in acute myocardial infarction: Possible implication in postinfarction left ventricular remodeling. J Interferon Cytokine Res 2002, 22: 223-229.
42. de Lemos JA, Morrow DA, Blazing MA, et al.: Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 2007, 50: 2117-2124.
43. Frangogiannis NG: The prognostic value of monocyte chemoattractant protein-1/CCL2 in acute coronary syndromes. J Am Coll Cardiol 2007, 50: 2125-2127.
44. Nathan C: Points of control in inflammation. Nature 2002, 420: 846-852.
45. McDermott DH, Yang Q, Kathiresan S, et al.: CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 2005, 112: 1113-1120.
46. Bustos C, Hernandez-Presa MA, Ortego M, et al.: HMGCoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998, 32: 2057-2064.
47. Rezaie-Majd A, Maca T, Bucek RA, et al.: Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002, 22: 1194-1199.
48. Frangogiannis NG: Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem 2006, 13: 1877-1893.